^
Association details:
| Biomarker: | KMT2A rearrangement + CD19 positive |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Kymriah (tisagenlecleucel-T) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy
Published date:
12/06/2021
Excerpt:
For patients with KMT2A-rearranged infant ALL (n=13), 2-year RFS was 67% (95%CI 45-99), and OS was 62% (95%CI 40-95)...Relapsed/refractory patients with high-risk cytogenetics, including KMT2A-rearranged infant ALL, demonstrated high RFS and OS probabilities at 2 years.
DOI:
10.1182/blood.2021012727
